{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010770","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.256610+00:00","generated_at":"2026-05-17T17:02:35.872025+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PTC Therapeutics Q2 2025: Sephience approved in EU and US; total revenue $179M; net loss narrows","bullets":["Sephience (sepiapterin) received EC and FDA approval with broad label for PKU across all ages and subtypes; global launch initiated.","Q2 total revenue $178.9M (vs $186.7M Q2 2024); DMD franchise $96M: Translarna $59.5M, Emflaza $36.4M.","Net loss improved to $64.8M from $99.2M; cash & securities $1.99B (up from $1.14B at Dec 31, 2024).","Entered agreement to buy out Censa sales milestone obligation for $225M upfront plus future milestones.","FY2025 revenue guidance $650-800M; vatiquinone PDUFA date Aug 19, 2025; positive Phase 2 HD results for votoplam."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010770","json":"https://secwatch.observer/filing/0001558370-25-010770.json","markdown":"https://secwatch.observer/filing/0001558370-25-010770.md","text":"https://secwatch.observer/filing/0001558370-25-010770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000155837025010770/0001558370-25-010770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000155837025010770/tmb-20250807x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:02:35.872025+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}